Abstract: The instant invention provides an immunogenic composition comprising an antigenic fragment of OspA protein of Borrelia burgdorferi and a chimeric protein containing antigenic fragments of different phylotypes of OspC protein of Borrelia burgdorferi. Vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing Lyme disease in dogs and/or protecting dogs from Lyme disease using the vaccines are also provided.

Abstract: Methods and systems of treating hydrocarbon containing formations are described herein. A system for treating a subterranean hydrocarbon containing formation includes a wellbore, and one or more packers positioned in the wellbore. At least one of the packers allows fluid to be injected in a subterranean hydrocarbon containing formation while allowing fluid to be produced from the wellbore.

Abstract: The present invention relates to methods of treating or reducing the risk of necrotizing enterocolitis (NEC) in an infant comprising orally administering an effective amount of a CpG-ODN. It is based, at least in part, on the results of experiments in which orally administered CpG-ODNs were observed to reduce the histopathology and markers of inflammation in a murine model for NEC. The present invention further provides for oral formulations of CpG-ODN for administration to infants.

Abstract: Exemplary embodiments of the present invention will assist patients with their investigation of, and decision making about, the treatments that are available to them using conjoint analysis methods that measure individual preferences for risk-associated treatment options, while maintaining an acceptable interview length. In exemplary embodiments, such individual preferences, known as “utilities” in economics literature, will be combined with evidence-based outcomes data regarding the probabilities of treatment outcomes; exemplary embodiments will use “decision analysis” and modified “conjoint analysis” methods, to dynamically generate for patients real-time individualized, evidence-based feedback, rankings and recommendations regarding medical treatment alternatives that are available to the patient based on the patient's medical condition and prognostic indicators.

Abstract: This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the NF-?B signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases.

Abstract: Disclosed are improved optical detection methods comprising multiplexed interferometric detection systems and methods for determining a characteristic property of a non-aqueous sample, together with various applications of the disclosed techniques.

Abstract: The current subject matter relates to indicating extent and location of myocardial ischemia in a patient. Electrodes can be placed on a body of the patient. Signal amplifiers can receive orthogonal electrical signals from the electrodes via three bipolar leads. The signal amplifiers can amplify the signals and send the amplified signals to analog to digital converters. The analog to digital converters can convert the amplified signals to digital signals. A computing device can execute a data analysis application that can receive these digital signals, generate QRS complexes associated with these signals, generate depolarization vectors associated with these QRS complexes, and then determine changes in magnitudes and directions of these vectors. Based on the changes in magnitudes and directions, the data analysis application can determine and display extent and location of myocardial ischemia in the patient. Related apparatus, systems, methods, techniques and articles are also described.

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

Abstract: The present disclosure provides tobacco inbred plants TN90 SRC, CMS TN90 SRC, KY14 SRC, CMS KY14 SRC, L8 SRC, NC775 SRC, CMS NC775 SRC, NC645 SRC, NC638 SRC, CMS NC638 SRC, TN86 SRC, and CMS TN86 SRC, and hybrids KY14×L8 SRC, NC7 SRC, and NCBH129 SRC. The present disclosure also provides parts of such plants and products made from those parts. The present disclosure also includes progeny of the provided plants including hybrids.

Abstract: Systems and methods for providing a noncollinear optical parametric amplifier (NOPA). Two approaches for classes of NOPA are described: phase-mask NOPA and Wollaston NOPA.

Abstract: Porous metal-organic frameworks (MOFs) and metallated porous MOFs are provided. Also provided are methods of metallating porous MOFs using atomic layer deposition and methods of using the metallated MOFs as catalysts and in remediation applications.

Abstract: Platinum(II) complexes having mixed ligands as anticancer agents. The central platinum atom is coordinated by two phosphine ligands and two heterocyclic thione ligands. Each heterocyclic thione ligand has a five-, six- or seven-membered heterocyclic ring with two nitrogen atoms at positions 1 and 3 of the ring and a thiocarbonyl group at position 2. Pharmaceutical compositions incorporated the platinum(II) complexes, methods of synthesizing the complexes and methods of treating cancers with the complexes or pharmaceutical compositions thereof are also described.

Abstract: The ionophore and polymer membrane selective for aluminum (III) ion provide an ionophore that is selective for aluminum (III) ion [Al3+]. The ionophore may be used as a dopant in a polymer membrane formed from a polymer matrix, e.g., poly (vinyl chloride) (PVC), and that may also include a plasticizer, such as dioctylphthalate (DOP) and o-nitrophenylloctyl ether (o-NPOE). The polymer membrane may be incorporated into an ion selective electrode (ISE) that can be used as a potentiometric sensor for the detection of Al3+ ions in wastewater.

Abstract: A method of and device for controlling a reflective color of a photonic crystal display device, capable of precisely controlling the distance between particles to display RGB full colors covering desired wavelength ranges. The method and device include using a mixed dispersion medium containing two or more kinds of solvents having different dielectric constants as a dispersion medium for a photonic crystal in a composition for a photonic crystal display device of which colors are controlled through the application of an electric field.

Abstract: The present invention relates to a composition comprising nanoparticles stabilized by an at least partially deprotonated biopolymer and a method for the preparation thereof.

Abstract: The invention provides electro-catalyst compositions for an anode electrode of a proton exchange membrane-based water electrolysis system. The compositions include a noble metal component selected from the group consisting of iridium oxide, ruthenium oxide, rhenium oxide and mixtures thereof, and a non-noble metal component selected from the group consisting of tantalum oxide, tin oxide, niobium oxide, titanium oxide, tungsten oxide, molybdenum oxide, yttrium oxide, scandium oxide, cooper oxide, zirconium oxide, nickel oxide and mixtures thereof. Further, the non-noble metal component can include a dopant. The dopant can be at least one element selected from Groups III, V, VI and VII of the Periodic Table. The compositions can be prepared using a surfactant approach or a sol gel approach. Further, the compositions are prepared using noble metal and non-noble metal precursors. Furthermore, a thin film containing the compositions can be deposited onto a substrate to form the anode electrode.

Abstract: Sensors for target entities having functionalized thereon, at least one amine-terminated aptamer specific to the target entity, and methods of making and using the same are described.

Abstract: A method for making a lithium battery cathode composite is provided. A mixed solution including a solvent, an iron salt, and a phosphate is provided. An alkaline solution is added in the mixed solution until the mixed solution has a pH value in a range from about 1.5 to about 5. The mixed solution is stirred to react the iron salt with the phosphate to form a number of iron phosphate precursor particles. The iron phosphate precursor particles are heated. A lithium source solution, a reducing agent, and the iron phosphate precursor particles are mixed to form a lithium iron phosphate precursor slurry. Outer surfaces of the lithium vanadium phosphate particles are coated with the lithium iron phosphate precursor.

Abstract: Herein provided is a new wheat cultivar designated ‘GA 041293-11E54’ as well as the seeds, plants and derivatives of the new wheat variety ‘GA 041293-11E54’ (such as cultivars and hybrids related thereto). This cultivar is a high grain yielding, medium maturing, good test weight, medium height line that has good resistance to races of leaf rust and stripe rust in Georgia and the Southeast, powdery mildew, Hessian flies, and wheat soil-borne mosaic virus. Also provided are tissue cultures of the new wheat variety ‘GA 041293-11E54’ and the plants regenerated therefrom. Methods for producing wheat plants by crossing the new wheat variety ‘GA 041293-11E54’ with itself or another wheat variety and plants produced by such methods are also provided.

Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.